DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at Oppenheimer lowered their FY2017 earnings per share estimates for shares of DexCom in a research report issued on Monday. Oppenheimer analyst S. Lichtman now expects that the medical device company will post earnings per share of ($0.62) for the year, down from their previous estimate of ($0.61). Oppenheimer currently has a “Buy” rating and a $67.00 price target on the stock. Oppenheimer also issued estimates for DexCom’s Q4 2017 earnings at $0.07 EPS, Q2 2018 earnings at ($0.17) EPS and FY2018 earnings at ($0.41) EPS.

Several other research firms have also weighed in on DXCM. BMO Capital Markets upped their price objective on DexCom to $74.00 and gave the company an “outperform” rating in a research note on Tuesday, December 12th. BidaskClub upgraded DexCom from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, December 12th. Northland Securities lowered DexCom from a “market perform” rating to an “under perform” rating and set a $85.00 price target on the stock. in a research report on Thursday, January 4th. Jefferies Group increased their price target on DexCom from $58.00 to $70.00 and gave the stock a “buy” rating in a research report on Friday, December 22nd. Finally, ValuEngine lowered DexCom from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. Three investment analysts have rated the stock with a sell rating, six have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $67.44.

Shares of DexCom (DXCM) opened at $54.67 on Wednesday. DexCom has a 12 month low of $42.62 and a 12 month high of $86.32. The company has a debt-to-equity ratio of 0.84, a quick ratio of 5.50 and a current ratio of 5.86.

In other DexCom news, insider Terrance H. Gregg sold 10,000 shares of the company’s stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $56.86, for a total transaction of $568,600.00. Following the transaction, the insider now owns 484,559 shares of the company’s stock, valued at approximately $27,552,024.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Kevin R. Sayer sold 12,000 shares of the company’s stock in a transaction on Monday, November 20th. The stock was sold at an average price of $55.00, for a total value of $660,000.00. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 48,140 shares of company stock worth $2,743,281. Company insiders own 1.70% of the company’s stock.

A number of large investors have recently bought and sold shares of the business. American International Group Inc. acquired a new position in shares of DexCom in the 4th quarter valued at $116,000. Advisor Group Inc. lifted its stake in shares of DexCom by 104.9% in the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after purchasing an additional 837 shares during the period. Thompson Davis & CO. Inc. acquired a new position in shares of DexCom in the 4th quarter valued at $137,000. Zions Bancorporation lifted its stake in shares of DexCom by 36,222.2% in the 3rd quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock valued at $160,000 after purchasing an additional 3,260 shares during the period. Finally, Toronto Dominion Bank lifted its stake in shares of DexCom by 251.0% in the 3rd quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock valued at $178,000 after purchasing an additional 2,608 shares during the period.

TRADEMARK VIOLATION WARNING: “DexCom, Inc. (DXCM) Forecasted to Earn FY2017 Earnings of ($0.62) Per Share” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was illegally stolen and reposted in violation of international copyright legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2018/02/14/dexcom-inc-dxcm-forecasted-to-earn-fy2017-earnings-of-0-62-per-share.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Earnings History and Estimates for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.